Altman Peter purchased $4K of BCDA

Altman Peter (President and CEO) purchased 4,300 shares of BioCardia, Inc. (BCDA) at an average of $0.87 ($0.86–$0.88) across 2 trades over 2026-07-14 to 2026-07-15.

Original reporting
SEC EDGAR · Altman Peter
Published Jul 15, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BCDA
Bullish
medium confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

The CEO’s open-market purchase is a sentiment input but lacks accompanying fundamental disclosures in the text, limiting trading impact.

02

Market read

Traders may note the insider buy as a small positive signal, but it is unlikely to be a standalone catalyst without additional company-specific developments.

03

What to watch

The filing does not indicate whether the purchase was opportunistic versus planned, and the article does not provide any concurrent company news (financing, trial, guidance) that would validate the signal.

Relevance 4/10Novelty 3/10Timing: Form 4 filed July 15, covering purchases on July 14-15.

Background

The article is an SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA).

Company-level read

Ticker impact

$BCDABullishMedium confidence
Context

BioCardia CEO Altman Peter reported an open-market purchase of 4,300 shares at about $0.873 weighted average via Form 4 filed July 15.

Expected impact

Likely limited, short-lived sentiment effect; no clear directional edge without corroborating company-specific news.

Evidence & confidence

Form 4 insider purchases can be informative, but the article provides only transaction details (size, price range) with no accompanying operational update. The trade size is small relative to typical market-moving thresholds, and there is no 10b5-1 plan context.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions and may not reflect a new view on fundamentals, especially without a stated rationale.

Key entities

  • BioCardia, Inc.

    Company whose CEO insider purchase is disclosed on SEC Form 4.

  • Altman Peter

    President and CEO reporting an open-market purchase of BCDA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.